Translational Approaches in Rare Diseases

Abstract

Rare diseases -- defined as conditions affecting fewer than 1 in 2,000 individuals in the EU -- collectively affect 30 million Europeans across approximately 7,000 distinct disorders, yet the median time from symptom onset to correct diagnosis remains 4.8 years, fewer than 6% of rare diseases have an approved therapy, and clinical trial recruitment averages just 58% of target enrolment. The translational pipeline for rare diseases faces unique challenges: small patient populations make traditional RCTs impractical, natural history data is sparse, and the commercial incentive for drug development is limited despite orphan drug legislation. We analysed the translational landscape across 842 rare disease research programmes tracked by the European Reference Networks (ERNs) and four national rare disease registries (Estonia, France, Germany, and Spain) from 2010 to 2022, covering inborn errors of metabolism, neuromuscular disorders, rare immunodeficiencies, and rare cancers. We compared five translational frameworks: natural history study-driven development, platform and basket trial designs, gene therapy pipelines, drug repurposing through computational screening, and patient registry-integrated evidence generation. Our Rare Disease Translational Score (RDTS) integrates diagnostic odyssey reduction, therapy development success rate, trial recruitment efficiency, evidence generation speed, and patient access equity. Patient registry-integrated evidence generation achieved the highest RDTS (0.918) by enabling real-world single-arm studies with external controls that reduced evidence generation time by 3.2 years. Gene therapy pipelines (RDTS 0.906) achieved the highest per-programme therapy approval rate (18.4%) but at extreme cost (median EUR 1.2 million per patient).